Redeye strengthens its positive view of Teneo AI following preliminary Q4 figures showing a substant...
Q4e: Clean paper EBIT of ~PLN 10m Paper prices down, demand muted Fair value range of SEK 40-80 Thi...
Redeye leaves a research update following Klaria Pharma’s recent announcement of a licensing agreeme...
Preliminary Q4 EBITA ~40% below FactSet consensus We expect consensus to cut '25 EBITA by ~15% and '...
Northbaze Group AB will receive approximately SEK 5.
Redeye comments on Nanologica following the annonucement of a SEK8.
Redeye comments on Sivers Semiconductors following the announcement that the company will receive an...
Redeye comments on CLS’s recap of 2024 and outlook for 2025-2026.
Redeye briefly comments on Physitrack’s announcement to streamline its subsidiary, Champion Health, ...
Redeye leaves a comment following OncoZenge’s announcement yesterday of having entered into a non-bi...
Redeye endorses today’s news that Elicera has received an orphan drug designation in the US for ELC-...
Redeye comments on Iconovo’s collaboration with Lonza to develop a reformulated obesity treatment.
Redeye comments on Arise’s new SEK50m share repurchase program, refinancing its green facility of EU...
Redeye initiates coverage of OEM International, a niche acquirer of technology trading SMEs that has...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 10 januari 2025 att Bolaget har erhållit ty...
Henrik Andersson, who has served as CEO of Northbaze since 2018, has informed the board of directors...
Redeye makes minor revisions to estimates ahead of Enea’s Q4 2024 report due on 30 January 2025.
Redeye comments on SynAct’s successful rights issue.
Nexttobe, existing investor Ulf Landegren, certain board members, senior executives and guarantee co...
Redeye provides a comment on Xspray following yesterday's press release announcing a delay in the re...